Brain serotonin transporter binding in non‐depressed patients with Parkinson's disease
- 11 April 2007
- journal article
- Published by Wiley in European Journal of Neurology
- Vol. 14 (5), 523-528
- https://doi.org/10.1111/j.1468-1331.2007.01727.x
Abstract
Early post-mortem data suggest that damage to brain serotonin neurones might play a role in some features (e.g., depression) of Parkinson's disease (PD). However, it is not known whether such damage is a typical characteristic of living patients with PD or whether the changes are regionally widespread. To address this question we measured, by positron emission tomography imaging, levels of the brain serotonin transporter (SERT), a marker for serotonin neurones, as inferred from binding of [11C]-3-amino-4-(2-dimethylaminomethyl-phenylsulfanyl)-benzonitrile (DASB), a second generation SERT radioligand, in subcortical and cerebral cortical brain areas of clinically advanced non-depressed (confirmed by structured psychiatric interview) patients with PD. SERT binding levels in PD were lower than those in controls in all examined brain areas, with the changes statistically significant in orbitofrontal cortex (-22%), caudate (-30%), putamen (-26%), and midbrain (-29%). However, only a slight non-significant reduction (-7%) was observed in dorsolateral pre-frontal cortex, an area implicated in major depression. Our imaging data suggests that a modest, regionally widespread loss of brain serotonergic innervation might be a common feature of advanced PD. Further investigation will be required to establish whether SERT binding is more or less decreased in those patients with PD who also have major depressive disorder.Keywords
This publication has 21 references indexed in Scilit:
- Review of the therapeutic management of Parkinson's disease. Report of a joint task force of the European Federation of Neurological Societies (EFNS) and the Movement Disorder Society‐European Section (MDS‐ES). Part II: late (complicated) Parkinson's diseaseEuropean Journal of Neurology, 2006
- A review of the receptor-binding and pharmacokinetic properties of dopamine agonistsClinical Therapeutics, 2006
- Regional distribution of serotonin transporter protein in postmortem human brain: Is the cerebellum a SERT-free brain region?Nuclear Medicine and Biology, 2005
- Effects of reduced endogenous 5‐HT on the in vivo binding of the serotonin transporter radioligand 11C‐DASB in healthy humansSynapse, 2004
- Serotonin Transporter Occupancy of Five Selective Serotonin Reuptake Inhibitors at Different Doses: An [11C]DASB Positron Emission Tomography StudyAmerican Journal of Psychiatry, 2004
- Occupancy of Serotonin Transporters by Paroxetine and Citalopram During Treatment of Depression: A [11C]DASB PET Imaging StudyAmerican Journal of Psychiatry, 2001
- β-blocker Binding to Human 5-HT1A Receptors in vivo and in vitro Implications for Antidepressant TherapyNeuropsychopharmacology, 2000
- Distribution Volume Ratios without Blood Sampling from Graphical Analysis of PET DataJournal of Cerebral Blood Flow & Metabolism, 1996
- Measurement of Radiotracer Concentration in Brain Gray Matter Using Positron Emission Tomography: MRI-Based Correction for Partial Volume EffectsJournal of Cerebral Blood Flow & Metabolism, 1992
- A quantitative model for the in vivo assessment of drug binding sites with positron emission tomographyAnnals of Neurology, 1984